21 September 2026
21 September 2026
The financing aims to bolster CardiaCare’s clinical programme for AFib indications.
mAbxience will lead the development and production of the biosimilar candidate at its manufacturing facilities in Argentina and Spain.
The Triton 1 system is indicated for diagnostic procedures and aims to address challenges with existing endoscope technology.
The development marks the fourth antibody-drug conjugate from Akeso to reach the clinical stage.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
